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Circulating tumor cells in the cerebrospinal fluid: “tapping” into 
diagnostic and predictive potential
Bishoy Faltas
Metastatic spread of breast cancer into the central 
nervous system (CNS) carries an especially ominous 
prognosis. Successful treatment depends on early and 
accurate diagnosis [1]. Therefore, it is of paramount clinical 
importance to develop sensitive and specific methods to 
detect circulating tumor cells (CTCs) in the cerebrospinal 
fluid  (CSF).  Routine  cytological  examination  of  the 
cerebrospinal fluid for tumor cells has many limitations 
including low sensitivity necessitating repeated lumbar 
punctures to increase the diagnostic yield [2]. In the 
October issue of Oncotarget, Patel et al developed a method 
to adapt the FDA approved CellSearch platform to isolate 
CTCs from the CSF after spiking them into blood [3]. 
This novel approach adds a “molecular dimension” to the 
detection of malignant epithelial cells in the CSF. It hones 
in on single cells and begins to characterize their surface 
markers thus opening the door to a better understanding 
of their role in the metastatic cascade. The CellSearch 
system defines CTCs as EpCAM+, Cytokeratin+, CD45- 
nucleated cells. These cells, when isolated from the CSF, 
may represent a special subpopulation of CTCs capable 
of surviving the perilous journey in the blood stream and 
subsequent invasion of the CNS. The next logical step in 
understanding the biology of this unique cell population 
will be to search for markers that would predict special 
affinity for homing into and invading the CNS, surviving 
and  proliferating  (i.e.  stem  cell  markers)  or  for  drug 
resistance [4]. Studying ER/PR and HER-2 concordance 
between primary or metastatic tumor sites and CTCs in 
the CSF could also have profound implications. Further 
studies are needed to create surface marker and genetic 
“profiles” of this important subset of CTCs. This study 
also demonstrated correlation between CTC counts in 
the  CSF  and  the  administration  of  chemotherapeutic 
agents, a pattern that mirrors that observed with CTCs 
in the peripheral blood of patients with metastatic breast 
cancer. Previous studies have confirmed the validity of 
circulating tumor cell counts in predicting progression 
free survival (PFS) and overall survival (OS) in patients 
with metastatic breast cancer. For instance, in one study of 
metastatic breast cancer, patients with more than 5 CTCs 
had lower PFS (2.7 months vs. 7.0 months, P<0.001) and 
shorter OS (10.1 months vs. >18 months, P<0.001). These 
differences persisted at the first follow-up visit after the 
initiation of therapy [5]. It would be interesting to see if 
larger studies confirm similar prognostic and predictive 
correlation between CTC counts in the CSF and survival 
or response to therapy. Our understanding of the role of 
CTCs in the biology of metastases continues to evolve. 
This valuable study sheds the light on a subset of CTCs 
capable of invading the blood brain barrier to reach the 
CNS.  Further  characterization  and  profiling  of  CTCs 
in the CSF is likely to yield valuable insights into the 
biology and the behavior of this important subset of cells 
and to improve our understanding of how CNS metastases 
occur. Correlation between CTCs counts, their biological 
characteristics and clinical outcomes will continue to 
make this area both promising and clinically relevant.
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